Last reviewed · How we verify
Combination 600
Combination 600 is a combination of two or more drugs that work together to treat a specific condition.
Combination 600 is a combination of two or more drugs that work together to treat a specific condition. Used for Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition].
At a glance
| Generic name | Combination 600 |
|---|---|
| Sponsor | Nuon Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of Combination 600 is not well-documented, but it is believed to work by targeting multiple pathways involved in the disease process.
Approved indications
- Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition]
Common side effects
- Unknown
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- Linezolid Plus Standard of Care (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination 600 CI brief — competitive landscape report
- Combination 600 updates RSS · CI watch RSS
- Nuon Therapeutics, Inc. portfolio CI